Adaptive Biotechnologies Corp — Director's Dealing 2020

Oct 8, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptive Biotechnologies Corp (ADPT)
CIK: 0001478320
Period of Report: 2020-10-06

Reporting Person: BALDO LANCE (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-06	Common Stock	M	6250	$7.80	Acquired	6250	Direct
2020-10-06	Common Stock	S	4236	$48.90	Disposed	2014	Direct
2020-10-06	Common Stock	S	2014	$49.84	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-06	Stock Option (Right to Buy)	$7.80	M	6250	Disposed	2029-05-06	Common Stock (6250)	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020.

F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.44 to 49.39, inclusive.

F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $49.47 to 50.065, inclusive.

F4: The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested.